ClinicalTrials.gg
CompletedNCT02420262Updated Mar 29, 2018Results posted

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of insulin degludec/liraglutide and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 117 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-29.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
17th of 70
506 · median 384
Started
2015
with 1 other
Phase 3
49 of 70
2 open now
Registered
43rd of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment, is one of 2 that started in 2015, is one of 49 in phase 3, and was the 43rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 506 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, age at least 18 years at the time of signing
  • Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening
  • (glycosylated ) 7.0-10.0% [53mmol/mol-86mmol/mol] (both inclusive) by central laboratory analysis
  • Current treatment with IGlar (insulin glargine) for at least 90 calendar days prior to screening
  • Stable daily dose of IGlar between 20 units and 50 units (both inclusive) for at least 56 calendar days prior to screening. Individual fluctuations of plus/minus 10% within the 56 calendar days prior to screening are acceptable, however on the day of screening total daily dose should be within the range of 20 units-50 units both inclusive
  • Stable daily dose of metformin (at least 1500 mg or max tolerated dose) for at least 90 calendar days prior to screening
  • (BMI) below or equal to 40 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 calendar days before screening
  • Anticipated initiation or change in concomitant medications in excess of 14 calendar days known to affect weight or glucose metabolism, such as weight loss/modifying (e.g.; sibutramine, orlistat, thyroid hormones, )
  • Impaired liver function, defined as (ALT) at least 2.5 times
  • Renal impairment (electronic case report form) below 60 mL/min/1.73 m\^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
  • Screening calcitonin at least 50 ng/L
  • History of pancreatitis (acute or chronic)
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
506 participants (actual)

Study arms

  • Experimental
    IDegLira

    Drug: insulin degludec/liraglutide

  • Active comparator
    IGlar plus IAsp

    Drug: insulin glargine · Drug: insulin aspart

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.

  • Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.

  • Injected s.c./subcutaneously (under the skin) before each main meal.

07

What researchers measure

Primary outcomes

  1. Change in HbA1c (Glycosylated Haemoglobin)

    Change in HbA1c values after 26 weeks of treatment.

    Time frame: Week 0, Week 26

Secondary outcomes

  1. Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes.

    Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia.

    Time frame: Weeks 0-26

  2. Change in Body Weight

    Change in body weight after 26 weeks of treatment.

    Time frame: Week 0, Week 26

  3. Responder for HbA1c Below 7.0%

    Number of subjects with HbA1c below 7% after 26 weeks of treatment.

    Time frame: After 26 weeks of treatment

  4. Responder for HbA1c Below or Equal to 6.5 %

    Number of subjects with HbA1c below 6.5% after 26 weeks of treatment.

    Time frame: After 26 weeks of treatment

08

Results

Posted Dec 7, 2017

Participant flow

The trial was conducted at 89 sites in 12 countries: Argentina (3 sites), Czech Republic (5 sites), France (3 sites), Greece (6 sites), Hungary (3 sites), Israel (6 sites), Mexico (3 sites), Russia (7 sites), Slovakia (5 sites), Spain (6 sites), Turkey (5 sites) and United States (37 sites).

Participant flow — Overall Study
MilestoneIDegLiraIGlar + IAsp
Started252254
Exposed252253
Completed250249
Not completed25
Withdrew: Adverse event10
Withdrew: Withdrawal by subject14
Withdrew: Unclassified01

Outcome measures

PrimaryChange in HbA1c (Glycosylated Haemoglobin)

Change in HbA1c values after 26 weeks of treatment.

Time frame:
Week 0, Week 26
Reported as:
Least squares mean · Percentage of glycosylated haemoglobin
Change in HbA1c (Glycosylated Haemoglobin)
Percentage of glycosylated haemoglobinIDegLiraIGlar + IAsp
Change in HbA1c (Glycosylated Haemoglobin)-1.48 ± 0.05-1.46 ± 0.05
Statistical analysis
  • IDegLira vs IGlar + IAsp · Mixed Models Analysis · p = <0.0001 · Treatment contrast: -0.02 · 95% CI -0.16 to 0.12
SecondaryNumber of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes.

Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia.

Time frame:
Weeks 0-26
Reported as:
Number · Number of episodes
Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes.
Number of episodesIDegLiraIGlar + IAsp
Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes.129975
Statistical analysis
  • IDegLira vs IGlar + IAsp · Negative binomial regression model · p = <0.0001 · Treatment ratio: 0.11 · 95% CI 0.08 to 0.17Superiority for IDegLira vs basal-bolus was considered confirmed if the 95% confidence interval for the treatment rate ratio was entirely below 1.0.
SecondaryChange in Body Weight

Change in body weight after 26 weeks of treatment.

Time frame:
Week 0, Week 26
Reported as:
Least squares mean · kg
Change in Body Weight
kgIDegLiraIGlar + IAsp
Change in Body Weight-0.93 ± 0.222.64 ± 0.22
Statistical analysis
  • IDegLira vs IGlar + IAsp · Mixed Models Analysis · p = <0.0001 · Treatment difference: -3.57 · 95% CI -4.19 to -2.95Superiority for IDegLira vs basal-bolus was considered confirmed if the 95% confidence interval for the treatment difference was below 0 or equal to zero.
SecondaryResponder for HbA1c Below 7.0%

Number of subjects with HbA1c below 7% after 26 weeks of treatment.

Time frame:
After 26 weeks of treatment
Reported as:
Count of participants · Participants
Responder for HbA1c Below 7.0%
ParticipantsIDegLiraIGlar + IAsp
Yes157156
No8177
SecondaryResponder for HbA1c Below or Equal to 6.5 %

Number of subjects with HbA1c below 6.5% after 26 weeks of treatment.

Time frame:
After 26 weeks of treatment
Reported as:
Count of participants · Participants
Responder for HbA1c Below or Equal to 6.5 %
ParticipantsIDegLiraIGlar + IAsp
Yes118104
No120129

Adverse events

Collected over Adverse events (AEs) were collected from the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment (26 weeks + 7 days of follow-up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegLira—12/252 (4.8%)84/252 (33.3%)
IGlar + IAsp—10/253 (4%)79/253 (31.2%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventIDegLiraIGlar + IAsp
Angina unstableCardiac disorders1/2520/253
Atrial fibrillationCardiac disorders1/2520/253
Atrial flutterCardiac disorders1/2520/253
Cardiac failureCardiac disorders1/2520/253
Chest painGeneral disorders1/2520/253
Diabetic foot infectionInfections and infestations1/2520/253
GastroenteritisInfections and infestations1/2520/253
Hepatic cystHepatobiliary disorders1/2520/253
HypoglycaemiaMetabolism and nutrition disorders1/2520/253
Postoperative wound infectionInfections and infestations1/2521/253
Most frequent other events
Most frequent other events
EventIDegLiraIGlar + IAsp
NasopharyngitisInfections and infestations12/25230/253
NauseaGastrointestinal disorders28/2524/253
InfluenzaInfections and infestations18/25212/253
HeadacheNervous system disorders14/25218/253
Upper respiratory tract infectionInfections and infestations15/25217/253
DiarrhoeaGastrointestinal disorders16/25210/253
Diabetic retinopathyEye disorders9/25214/253

Baseline characteristics

The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and subjects contributed to the evaluation "as randomised"

Age, Continuous
Age, Continuous(years)IDegLiraIGlar + IAspTotal
Mean58.6 ± 9.058.0 ± 8.658.3 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)IDegLiraIGlar + IAspTotal
Female142137279
Male110117227
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegLiraIGlar + IAspTotal
Mean8.21 ± 0.768.24 ± 0.818.22 ± 0.78
Body Weight
Body Weight(kg)IDegLiraIGlar + IAspTotal
Mean87.2 ± 16.088.2 ± 17.287.7 ± 16.6
09

Study locations

117 sites
  • Novo Nordisk Investigational Site
    Tuscumbia, Alabama 35674, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Bermuda Dunes, California 92203, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Lincoln, California 95648, United States
  • Novo Nordisk Investigational Site
    Lomita, California 90717, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Montclair, California 91763, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    Waterbury, Connecticut 06708, United States
  • Novo Nordisk Investigational Site
    Palm Harbor, Florida 34684-3609, United States
  • Novo Nordisk Investigational Site
    Plantation, Florida 33324, United States
  • Novo Nordisk Investigational Site
    Blackfoot, Idaho 83221, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Skokie, Illinois 60077, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Investigational Site
    Natchitoches, Louisiana 71457-5881, United States
  • Novo Nordisk Investigational Site
    Shreveport, Louisiana 71105, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Waltham, Massachusetts 02453, United States
  • Novo Nordisk Investigational Site
    Billings, Montana 59101, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89109, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Jackson Heights, New York 11372, United States
  • Novo Nordisk Investigational Site
    New Windsor, New York 12553, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Shelby, North Carolina 28150, United States
  • Novo Nordisk Investigational Site
    Statesville, North Carolina 28625, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45245, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43213, United States
  • Novo Nordisk Investigational Site
    Dayton, Ohio 45439, United States
  • Novo Nordisk Investigational Site
    Mason, Ohio 45040-6815, United States
  • Novo Nordisk Investigational Site
    Altoona, Pennsylvania 16602, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19152, United States
  • Novo Nordisk Investigational Site
    Greer, South Carolina 29651, United States
  • Novo Nordisk Investigational Site
    Murrells Inlet, South Carolina 29576, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77024, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77058, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78229, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77478, United States
  • Novo Nordisk Investigational Site
    Sugar Land, Texas 77479, United States
  • Novo Nordisk Investigational Site
    Midlothian, Virginia 23114, United States
  • Novo Nordisk Investigational Site
    Spokane, Washington 99208, United States
  • Novo Nordisk Investigational Site
    Caba, C1440AAD, Argentina
  • Novo Nordisk Investigational Site
    Capital Federal, 1405, Argentina
  • Novo Nordisk Investigational Site
    Córdoba, X5006IKK, Argentina
  • Novo Nordisk Investigational Site
    Salta, 4400, Argentina
  • Novo Nordisk Investigational Site
    Brno, 65691, Czechia
  • Novo Nordisk Investigational Site
    Hradec Králové, 500 36, Czechia
  • Novo Nordisk Investigational Site
    Olomouc, Lazce, 77900, Czechia
  • Novo Nordisk Investigational Site
    Olomouc, 77900, Czechia
  • Novo Nordisk Investigational Site
    Pardubice, 53002, Czechia
  • Novo Nordisk Investigational Site
    Prostejov, 79601, Czechia
  • Novo Nordisk Investigational Site
    Angers, 49000, France
  • Novo Nordisk Investigational Site
    Bourgoin-jallieu, 38302, France
  • Novo Nordisk Investigational Site
    Brest, 29609, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Le Coudray, 28630, France
  • Novo Nordisk Investigational Site
    Le Creusot, 71200, France
  • Novo Nordisk Investigational Site
    MARSEILLE cedex 08, 13285, France
  • Novo Nordisk Investigational Site
    Marseille, 13008, France
  • Novo Nordisk Investigational Site
    Saint Herblain, 44800, France
  • Novo Nordisk Investigational Site
    Saint Priest en Jarez, 42270, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67098, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Athens, GR-11527, Greece
  • Novo Nordisk Investigational Site
    Chalkida, Evia, GR-34100, Greece
  • Novo Nordisk Investigational Site
    Ioannina, 45500, Greece
  • Novo Nordisk Investigational Site
    Larissa, GR-41110, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-54642, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-57001, Greece
  • Novo Nordisk Investigational Site
    Budapest, 1115, Hungary
  • Novo Nordisk Investigational Site
    Gyula, H-5700, Hungary
  • Novo Nordisk Investigational Site
    Szeged, H-6720, Hungary
  • Novo Nordisk Investigational Site
    Szombathely, H-9700, Hungary
  • Novo Nordisk Investigational Site
    Tatabánya, 2800, Hungary
  • Novo Nordisk Investigational Site
    Haifa, 35152, Israel
  • Novo Nordisk Investigational Site
    Holon, 58100, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Kfar Saba, 44281, Israel
  • Novo Nordisk Investigational Site
    Nahariya, 22100, Israel
  • Novo Nordisk Investigational Site
    Rehovot, 76100, Israel
  • Novo Nordisk Investigational Site
    Guadalajara, Jalisco 44650, Mexico
  • Novo Nordisk Investigational Site
    Mexico City, México, D.F. 03300, Mexico
  • Novo Nordisk Investigational Site
    Aguascalientes, 20230, Mexico
  • Novo Nordisk Investigational Site
    Durango, 34000, Mexico
  • Novo Nordisk Investigational Site
    Kazan, 420073, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 117036, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 191119, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 194291, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 194354, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199034, Russian Federation
  • Novo Nordisk Investigational Site
    Volgograd, 400131, Russian Federation

Showing the first 100 of 117 sites across 12 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, Gron R, Halladin N, Jodar E. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabetes Care. 2018 May;41(5):1009-1016. doi: 10.2337/dc17-1114. Epub 2018 Feb 26. PubMed 29483185 ↗
  • Billings LK, Agner BFR, Altuntas Y, Gron R, Halladin N, Klonoff DC, Tentolouris N, Jodar E. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial. J Diabetes Sci Technol. 2021 May;15(3):636-645. doi: 10.1177/1932296820906888. Epub 2020 Feb 28. PubMed 32107930 ↗
  • Meneghini L, Doshi A, Gouet D, Vilsboll T, Begtrup K, Orsy P, Ranthe MF, Lingvay I. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. Diabet Med. 2020 Feb;37(2):267-276. doi: 10.1111/dme.14178. Epub 2019 Nov 28. PubMed 31705547 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Oct 2016, 14 months.

Results were first posted in Dec 2017, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2015
First posted
Apr 17, 2015
StartActual
Jul 26, 2015
Primary completionActual
Oct 5, 2016
CompletionActual
Oct 5, 2016
Results first posted
Dec 7, 2017
Last update
Mar 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02420262
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 17, 2015
Start date
Jul 26, 2015
Primary completion
Oct 5, 2016
Completion
Oct 5, 2016
Results posted
Dec 7, 2017
Last update
Mar 29, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion